RxDoctor Payments Data

Michelle Kirk

Nurse Practitioner · Hutchinson, KSNPI 1356792014

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $56,924 of the $58,252 with a category attached, or 97.7%. Pfizer accounts for 97.9% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2022 at $57,205 and has fallen 99.4% since, to $333 in 2025. Among nurse practitioner clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$58,252in general payments, 2019–2025

Across 114 payments — averaging $510.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$57K
  • AbbVie$414
  • Novo Nordisk$132
  • Amgen$126
  • Sumitomo Pharma America, Inc.$93
  • Lilly USA, LLC$91
  • plus $367 from 13 others

What the payments were for

  • Consulting fees$56,92498%
  • Food & beverage$1,3282%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$58,252 in reported general payments places this provider in the 95th percentile of 1,326 nurse practitioner providers in Kansas.

See all nurse practitioner providers in Kansas

Medicare billing

Part B allowed, 2024
$4,834
Medicare patients
83
Services billed
161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide13$11,920
Doxycycline Hyclate36$512
Fluticasone Propionate40$425
Valsartan18$422
Divalproex Sodium ErDivalproex Sodium12$418
Albuterol Sulfate HfaAlbuterol Sulfate12$378
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav44$350
Levothyroxine Sodium46$304
Escitalopram Oxalate34$301
Atorvastatin Calcium29$281
Metoprolol Succinate18$226
Lansoprazole15$187
Losartan Potassium27$168
Methylprednisolone27$157
Omeprazole18$147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$91$11,92013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,326 nurse practitioner providers in Kansas.

Other nurse practitioner in Hutchinson

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →